Clinical trial
An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Oral Histone Deacetylase (HDAC)-Inhibitor Abexinostat, as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma (FL)
NCT03934567 is registered in ClinicalTrials.gov with Xynomic Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Oral Histone Deacetylase (HDAC)-Inhibitor Abexinostat, as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma (FL)
- Lead sponsor
- Xynomic Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 22, 2020
- Completion date
- October 30, 2025
- Enrollment
- 87 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.